WO2002013825A8 - Novel pharmaceutical use of quinnoline derivatives - Google Patents

Novel pharmaceutical use of quinnoline derivatives

Info

Publication number
WO2002013825A8
WO2002013825A8 PCT/GB2001/003588 GB0103588W WO0213825A8 WO 2002013825 A8 WO2002013825 A8 WO 2002013825A8 GB 0103588 W GB0103588 W GB 0103588W WO 0213825 A8 WO0213825 A8 WO 0213825A8
Authority
WO
WIPO (PCT)
Prior art keywords
quinnoline
derivatives
pharmaceutical use
novel pharmaceutical
prophylaxis
Prior art date
Application number
PCT/GB2001/003588
Other languages
French (fr)
Other versions
WO2002013825A1 (en
Inventor
Peter Machin
Original Assignee
Smithkline Beecham Plc
Peter Machin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0019973A external-priority patent/GB0019973D0/en
Priority claimed from GB0020001A external-priority patent/GB0020001D0/en
Priority claimed from GB0019988A external-priority patent/GB0019988D0/en
Priority claimed from GB0019990A external-priority patent/GB0019990D0/en
Application filed by Smithkline Beecham Plc, Peter Machin filed Critical Smithkline Beecham Plc
Priority to AU2001276556A priority Critical patent/AU2001276556A1/en
Publication of WO2002013825A1 publication Critical patent/WO2002013825A1/en
Publication of WO2002013825A8 publication Critical patent/WO2002013825A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method for the treatment and/or prophylaxis of cystic fibrosis, which method comprises the administration to a mammal in need thereof, of an effective, non-toxic, pharmaceutically acceptable amount of an NK3 antagonist.
PCT/GB2001/003588 2000-08-11 2001-08-09 Novel pharmaceutical use of quinnoline derivatives WO2002013825A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001276556A AU2001276556A1 (en) 2000-08-11 2001-08-09 Novel pharmaceutical use of quinnoline derivatives

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB0019990.1 2000-08-11
GB0019988.5 2000-08-11
GB0019973.7 2000-08-12
GB0019973A GB0019973D0 (en) 2000-08-12 2000-08-12 Novel use
GB0020001A GB0020001D0 (en) 2000-08-12 2000-08-12 Novel use
GB0020001.4 2000-08-12
GB0019988A GB0019988D0 (en) 2000-08-14 2000-08-14 Novel use
GB0019990A GB0019990D0 (en) 2000-08-14 2000-08-14 Novel use

Publications (2)

Publication Number Publication Date
WO2002013825A1 WO2002013825A1 (en) 2002-02-21
WO2002013825A8 true WO2002013825A8 (en) 2002-10-24

Family

ID=27447873

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/003588 WO2002013825A1 (en) 2000-08-11 2001-08-09 Novel pharmaceutical use of quinnoline derivatives

Country Status (2)

Country Link
AU (1) AU2001276556A1 (en)
WO (1) WO2002013825A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201018662A (en) 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
EP2986293A1 (en) 2013-04-19 2016-02-24 Astrazeneca AB A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2485014A1 (en) * 1980-06-20 1981-12-24 Pharmindustrie NOVEL DERIVATIVES OF (QUINOLYL-2, -3 OR -4) -1 (PIPERIDYL OR PYRROLIDINYL-2 OR -3) -2 OR -3 ETHANONE OR PROPANONE, PROCESSES FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS
EP0804419B1 (en) * 1994-05-27 2003-08-06 SmithKline Beecham Farmaceutici S.p.A. Quinoline derivatives as tachykinin nk 3 receptor antagonists
IT1270615B (en) * 1994-07-14 1997-05-07 Smithkline Beecham Farma USE OF QUINOLINE DERIVATIVES
JPH10512855A (en) * 1994-12-23 1998-12-08 スミスクライン・ビーチャム・コーポレイション Compounds and methods
GB9513121D0 (en) * 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
AR004735A1 (en) * 1995-11-24 1999-03-10 Smithkline Beecham Spa CHINOLEIN 4-AMIDO SUBSTITUTED, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT.
GB9601680D0 (en) * 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
US5929094A (en) * 1996-10-25 1999-07-27 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
SK159299A3 (en) * 1997-05-23 2000-06-12 Smithkline Beecham Spa Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists

Also Published As

Publication number Publication date
WO2002013825A1 (en) 2002-02-21
AU2001276556A1 (en) 2002-02-25

Similar Documents

Publication Publication Date Title
HUP0203312A3 (en) Pharmaceutically active sulfonamide derivatives, process for their preparation, and pharmaceutical compositions and their use
LU92381I2 (en) Macitentan and its pharmaceutically acceptable derivatives (OPSUMIT)
WO1997049394A3 (en) Sold oral dosage forms of valsartan
CA2363990A1 (en) Use of glycyrrhizin in the treatment of mastitis
WO2001041762A3 (en) Valdecoxib compositions
EP1719770A3 (en) Quinoline derivatives as antibacterials
HUP0101336A3 (en) Process for the preparation of perindopril and their pharmaceutically acceptable salts
CA2457361A1 (en) Opioid agonist formulations with releasable and sequestered antagonist
NO2010006I2 (en) Saxagliptin and its pharmaceutically acceptable salts, including Saxagliptin hydrochloride
AP9801272A0 (en) Use of an antagonist of ppar-alpha and ppr-gamma for the treatment of syndrom X.
AU2001280597A1 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
WO2001007432A3 (en) Aminopiperidine derivatives as antibacterials
HUP0301325A3 (en) Stabilized pharmaceutically effective composition and pharmaceutical composition comprising the same and process for preparation the composition
HK1060305A1 (en) Contraception process and administration form for the same
IL150895A0 (en) Oral, nasal and pulmonary formulations of copolymer-1
HK1054031A1 (en) Pharmaceutically active pyrrolidine derivatives
NZ515339A (en) Use of macrolide compounds for the treatment of dry eye
EP2138175A3 (en) Formulations comprising valsartan for treating diabetes or microalbuminuria
HK1054033A1 (en) 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
IL153540A0 (en) THE USE OF 7beta-HYDROXY-STEROID DERIVATIVES FOR THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS
HUP0303178A3 (en) Methods and compositions for reducing the taste of pharmaceutically active agents
WO2002013825A8 (en) Novel pharmaceutical use of quinnoline derivatives
PL357106A1 (en) Novel process for the preparation of alpha-(2-4-disulfophenyl)-n-tert-butylnitrone and pharmaceutically acceptable salts thereof
WO2003024445A1 (en) Drugs comprising combination of antithrombotic agent with pyrazolone derivative
AU2001284084A1 (en) Polyfluoroalkyltriazole derivatives, preparation and therapeutic use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP